Cipla Revs Up In US, Newer Markets To Cushion Against Volatility
Executive Summary
US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.
Operational Fixes At Cipla But All Eyes On Generic Advair
Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.